Sweetgreen Stock Plunges 13% on Weak Q2, Guidance Cut
💡 Puntos Clave
Sweetgreen's Q2 miss and guidance cut due to cyclospora outbreak overshadow improving traffic trends, making the stock risky in the near term.
What Happened: Sweetgreen's Q2 Miss and Guidance Cut
Sweetgreen (SG) shares tumbled more than 13% in morning trading after the fast-casual salad chain reported disappointing second-quarter results and slashed its full-year guidance. The company cited the impact of the cyclospora outbreak, which has deterred customers even though Sweetgreen has not been directly affected.
In Q2, same-store sales fell 6.2%, an improvement from the 12.8% decline in Q1, but still a significant drop. Revenue rose 3.8% to $192.7 million, missing the consensus estimate of $194.5 million. Restaurant-level profit margin contracted sharply from 18.9% to 13.1%, and adjusted EBITDA swung from a positive $6.4 million to a loss of $0.2 million.
The company's bottom line also worsened, with a GAAP loss per share of $0.22, wider than the $0.20 loss a year ago and worse than the expected $0.12 loss. Despite these misses, there were some positive signs: same-store traffic declined only 2%, and the company exited June with flat traffic, suggesting the core business was stabilizing.
However, the cyclospora outbreak, which began in mid-July, has disrupted that recovery. Management noted that same-store sales were down 600 basis points in July due to the outbreak, even though Sweetgreen does not use iceberg lettuce, the implicated item. As a result, the company cut its full-year same-store sales guidance to a decline of 7%-8% from a prior range of down 2%-4%.
Additionally, Sweetgreen now expects an adjusted EBITDA loss of $23 million to $27 million, a stark reversal from its earlier forecast of a profit of $1 million to $6 million. The company acknowledged that the pace and timing of recovery remain uncertain, leaving investors wary about the near-term outlook.
Why It Matters: Impact on Sweetgreen's Stock and Future
Sweetgreen's stock has been under pressure as the company struggles with declining sales and profitability. The Q2 results show that while the company was making progress in improving traffic, the cyclospora outbreak has thrown a wrench into its recovery. This is a significant setback because consumer confidence is crucial for a restaurant chain, and any perception of food safety issues can have lasting effects.
The guidance cut is particularly concerning because it signals that management expects the challenges to persist. The shift from a projected profit to a loss of up to $27 million in adjusted EBITDA is a major downgrade, reflecting both the sales decline and the costs associated with managing the outbreak's impact. This could strain the company's cash flow and delay its path to profitability.
From a competitive standpoint, Sweetgreen faces intense competition in the fast-casual space from players like Chipotle and CAVA. While Sweetgreen has a differentiated brand focused on healthy salads, the recent issues could give competitors an edge in winning over health-conscious consumers. The company's ability to regain customer trust and return to positive comparable sales growth will be critical.
Investors should also consider the broader context: the stock has been volatile, and this news adds to the uncertainty. The company's valuation may become more attractive if it can execute its turnaround plan, but the near-term risks are elevated. The market's reaction suggests that investors are skeptical about the company's ability to recover quickly.
Ultimately, this news matters because it affects Sweetgreen's financial health, competitive position, and investor sentiment. The company's future depends on its ability to navigate the current crisis and demonstrate that its underlying business model is sound.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight

Avoid SG stock until there are clear signs of recovery from the cyclospora impact and improved sales trends.
The guidance cut and negative sentiment from the outbreak create significant near-term headwinds. While the company was making progress, the uncertainty around recovery makes the stock risky. Investors should wait for evidence of stabilizing sales and margin improvement before considering a position.
¿Cómo Me Afecta?


